The Saudi Food and Drug Authority (SFDA) has imposed penalties totaling SAR678,400 on 24 pharmaceutical establishments for failing to provide their registered products in the local market, the authority announced in September 2024. The violations include not promptly reporting to the SFDA’s Drug Track and Trace System (RSD), failing to notify the SFDA of anticipated shortages or supply interruptions, and not maintaining adequate stock of their products. This enforcement action underscores the Kingdom’s commitment to ensuring the availability of essential medicines for all citizens and residents.
Context and Background
The SFDA, established in 2003 as the national authority responsible for regulating food, drugs, medical devices, and other health products, has been intensifying its oversight of the pharmaceutical sector. In August 2024, SFDA inspectors monitored 24 establishments and identified specific non-compliances: five failed to report directly to the RSD, nine did not provide their registered products, nine did not report expected shortages or supply interruptions, and one failed to maintain sufficient stock of all its registered products for at least six months. These violations contravene “The Registration Rules of Pharmaceutical, Herbal and Health Product Manufacturers and Their Products Guideline,” which mandates strict reporting and stock maintenance requirements.
Key Details
The SFDA stated that the penalties are in accordance with the guidelines, which require pharmaceutical and herbal manufacturers and warehouses to maintain sufficient stock for six months of all their registered products, based on annual consumption and need data reviewed by the SFDA. Any stock shortages must be addressed within a maximum of three months, unless the SFDA issues a decision to cancel the product registrations. Manufacturers and their representatives must also notify the SFDA of any anticipated shortages or interruptions in the supply of registered products for a duration of at least six months from the expected time of the disruption, and provide solutions to help address the shortage. The SFDA confirmed that penalties can reach up to SAR5 million, in addition to potential closure of the facility or cancellation of its license. The authority encourages reporting any violations by contacting the unified number (19999).
Implications and Impact
This enforcement action has significant implications for the pharmaceutical industry in Saudi Arabia. It sends a clear message that non-compliance with SFDA regulations will not be tolerated, and that the authority is actively monitoring and penalizing violations. For international observers, it demonstrates Saudi Arabia’s rigorous approach to healthcare governance and its commitment to protecting public health. The move also aligns with global best practices in drug regulation, where track-and-trace systems and supply chain transparency are increasingly prioritized to prevent shortages and ensure patient safety. Furthermore, it reinforces the Kingdom’s attractiveness as a market for pharmaceutical investment by ensuring a level playing field for compliant companies.
Vision 2030 Alignment
This initiative is closely tied to Saudi Vision 2030, which aims to strengthen the healthcare sector and ensure the well-being of citizens and residents. By enforcing strict compliance, the SFDA supports the Vision’s goals of enhancing quality of life, improving healthcare services, and fostering a robust and reliable pharmaceutical supply chain. As Saudi Arabia continues to transform its economy and society, robust regulatory frameworks like those implemented by the SFDA are essential to building trust and ensuring sustainable development in the health sector and beyond.
20 Questions
Q1. What is the total amount of penalties imposed by the SFDA on pharmaceutical establishments?
A1. The SFDA imposed penalties totaling SAR678,400 on 24 pharmaceutical establishments for non-compliance with regulations regarding the provision of registered products in the local market.
Q2. How many pharmaceutical establishments were penalized by the SFDA?
A2. The SFDA penalized 24 pharmaceutical establishments for various violations related to reporting and stock maintenance of registered products.
Q3. What are the specific violations identified by the SFDA?
A3. Violations included failure to report to the Drug Track and Trace System (RSD), not providing registered products, not reporting expected shortages, and not maintaining sufficient stock for at least six months.
Q4. What is the Drug Track and Trace System (RSD)?
A4. The RSD is an SFDA system that tracks and traces pharmaceutical products to ensure their authenticity and availability throughout the supply chain in Saudi Arabia.
Q5. How many establishments failed to report directly to the RSD?
A5. Five establishments failed to report directly to the SFDA’s Drug Track and Trace System (RSD), as identified during inspections in August 2024.
Q6. What are the requirements for maintaining stock of registered products?
A6. Manufacturers and warehouses must maintain sufficient stock for six months of all registered products, based on annual consumption data reviewed by the SFDA.
Q7. Within what timeframe must stock shortages be addressed?
A7. Any stock shortages must be addressed within a maximum of three months, unless the SFDA issues a decision to cancel the product registrations.
Q8. How far in advance must manufacturers notify the SFDA of anticipated shortages?
A8. Manufacturers must notify the SFDA of any anticipated shortages or supply interruptions at least six months before the expected disruption, and provide solutions.
Q9. What is the maximum penalty that the SFDA can impose for such violations?
A9. The penalties can reach up to SAR5 million, in addition to potential closure of the facility or cancellation of its license.
Q10. What guideline outlines these penalties and requirements?
A10. The penalties and requirements are outlined in “The Registration Rules of Pharmaceutical, Herbal and Health Product Manufacturers and Their Products Guideline.”
Q11. How can violations be reported to the SFDA?
A11. Violations can be reported by contacting the SFDA’s unified number (19999), as stated in their announcement.
Q12. What is the role of the SFDA in Saudi Arabia?
A12. The SFDA is the national authority responsible for regulating food, drugs, medical devices, and other health products to ensure safety, quality, and availability.
Q13. Why is this enforcement action important for public health?
A13. It ensures that pharmaceutical establishments comply with regulations, thereby guaranteeing the availability of essential medicines for citizens and residents across the Kingdom.
Q14. How does this action align with Saudi Vision 2030?
A14. It supports Vision 2030’s goals of enhancing healthcare quality, improving services, and building a reliable pharmaceutical supply chain for sustainable development.
Q15. What impact does this have on international pharmaceutical companies?
A15. It demonstrates Saudi Arabia’s rigorous regulatory environment, encouraging compliance and ensuring a level playing field for all companies operating in the Kingdom.
Q16. What was the timeframe for the inspections that led to these penalties?
A16. The inspections were conducted in August 2024, during which the SFDA monitored 24 establishments and identified the violations.
Q17. How many establishments failed to provide their registered products?
A17. Nine establishments failed to provide their registered products in the local market, as per the SFDA’s inspection findings.
Q18. How many establishments did not report expected shortages or supply interruptions?
A18. Nine establishments did not report expected shortages or supply interruptions, violating the SFDA’s reporting requirements.
Q19. What is the significance of maintaining six months of stock?
A19. It ensures a stable supply of medicines, preventing shortages that could affect patient care and public health in Saudi Arabia.
Q20. What other penalties can the SFDA impose beyond fines?
A20. The SFDA can also close the facility or cancel its license, in addition to fines of up to SAR5 million, for severe or repeated violations.
Reader Feedback
We value your thoughts. Please share your feedback on this article.
Your feedback helps us improve our coverage.